Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2019’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections

– The report reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cytomegalovirus (HHV-5) Infections therapeutics and enlists all their major and minor projects

– The report assesses Cytomegalovirus (HHV-5) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Abhelix LLC

AIMM Therapeutics BV

AlloVir Inc

Artemis Therapeutics Inc

Atara Biotherapeutics Inc

Biotest AG

Chengdu Rongsheng Pharmaceutical Co Ltd

China Biologic Products Holdings Inc

China Immunotech Co Ltd

Evrys Bio

Fate Therapeutics Inc

GlaxoSmithKline Plc

Helocyte Biosciences Inc

Hookipa Pharma Inc

Kadmon Corp LLC

Laboratoires Thea SA

Macrophage Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Moderna Therapeutics Inc

Okogen Inc

Phoenix Biotechnology Inc

Provention Bio Inc

Qurient Co Ltd

Savoy Pharmaceuticals Inc

SL VaxiGen Inc

Takeda Pharmaceutical Co Ltd

Themis Bioscience GmbH

Trellis Bioscience Inc

VBI Vaccines Inc

Vichem Chemie Research Ltd

Viramatix Sdn Bhd

Zhuhai Trinomab Biotechnology Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Cytomegalovirus (HHV-5) Infections Overview 6

Cytomegalovirus (HHV-5) Infections Therapeutics Development 7

Cytomegalovirus (HHV-5) Infections Therapeutics Assessment 21

Cytomegalovirus (HHV-5) Infections Companies Involved in Therapeutics Development 29

Cytomegalovirus (HHV-5) Infections Drug Profiles 41

Cytomegalovirus (HHV-5) Infections Dormant Projects 148

Cytomegalovirus (HHV-5) Infections Discontinued Products 152

Cytomegalovirus (HHV-5) Infections Product Development Milestones 153

Appendix 161

List of Tables

“List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Abhelix LLC, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by AIMM Therapeutics BV, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by AlloVir Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Artemis Therapeutics Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Atara Biotherapeutics Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Biotest AG, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by China Biologic Products Holdings Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by China Immunotech Co Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Evrys Bio, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Fate Therapeutics Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by GlaxoSmithKline Plc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Helocyte Biosciences Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Hookipa Pharma Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Kadmon Corp LLC, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Laboratoires Thea SA, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Macrophage Therapeutics Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Merck & Co Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Microbiotix Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Moderna Therapeutics Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Okogen Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Phoenix Biotechnology Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Provention Bio Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Qurient Co Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Savoy Pharmaceuticals Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by SL VaxiGen Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Themis Bioscience GmbH, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Trellis Bioscience Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by VBI Vaccines Inc, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Vichem Chemie Research Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Viramatix Sdn Bhd, H2 2019

Cytomegalovirus (HHV-5) Infections – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H2 2019

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2019

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2019 (Contd..2), H2 2019

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2019 (Contd..3), H2 2019

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2019 (Contd..4), H2 2019

Cytomegalovirus (HHV-5) Infections – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports